STOCK TITAN

eFFECTOR Therapeutics Inc - EFTR STOCK NEWS

Welcome to our dedicated news page for eFFECTOR Therapeutics (Ticker: EFTR), a resource for investors and traders seeking the latest updates and insights on eFFECTOR Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect eFFECTOR Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of eFFECTOR Therapeutics's position in the market.

Rhea-AI Summary
eFFECTOR Therapeutics, Inc. will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14th. The company is a leader in the development of selective translation regulator inhibitors for cancer treatment. The presentation will be available via live webcast and replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
conferences
-
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) has completed a registered direct offering, selling 1,488,834 shares of its common stock and short-term warrants to purchase an additional 1,488,834 shares. The offering generated approximately $15 million in gross proceeds, with H.C. Wainwright & Co. acting as the exclusive placement agent. The Company plans to utilize the funds for general corporate and working capital purposes, including research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
offering
-
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (EFTR) has announced a definitive agreement for the purchase and sale of 1,488,834 shares of its common stock and warrants to purchase up to the same number of shares at an offering price of $10.075 per share. The warrants will be exercisable immediately upon issuance, with an exercise price of $9.95 per share. The closing of the offering is expected soon, and the funds raised will be used for general corporate purposes and to support the development of its selective translation regulator inhibitors for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.74%
Tags
offering
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) announces a virtual investor R&D Day on January 24, 2024, to review the development progress of tomivosertib and zotatifin, including recently announced interim data from dose escalation and Phase 2 expansion cohorts of zotatifin in ER+ metastatic breast cancer patients. The company also previews anticipated 2024 milestones and topline results from the Phase 2b KICKSTART clinical trial of tomivosertib combined with pembrolizumab for the treatment of frontline NSCLC in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.84%
Tags
conferences
-
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) announced a 1-for-25 reverse stock split of its common stock, effective on January 12, 2024, to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market. The reverse split will reduce the number of issued and outstanding shares from approximately 74.9 million to 3.0 million shares, with the total authorized number of shares of common stock being reduced from 1,000,000,000 to 40,000,000 shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.84%
Tags
none
-
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) announced positive interim data from a Phase 1/2 clinical study of zotatifin in patients with estrogen receptor positive (ER+) metastatic breast cancer. The median progression free survival (mPFS) was 7.4 months in the ZFA expansion cohort, and zotatifin was generally well tolerated as dose escalation continues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.11%
Tags
clinical trial
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (EFTR) receives Fast Track designation from the FDA for zotatifin in combination with fulvestrant and abemaciclib as second- or third-line therapy for ER+/HER2- advanced or metastatic breast cancer. The company plans to present data updates and further development plans at the 2023 San Antonio Breast Cancer Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
clinical trial
-
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) announced the presentation of new clinical data from a Phase 1/2 study of zotatifin in patients with ER+ metastatic breast cancer at the San Antonio Breast Cancer Symposium 2023. The company plans to discuss the trial results and provide updates on zotatifin development at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.72%
Tags
conferences clinical trial
-
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) reported financial results for Q3 2023 and provided a corporate update. The company is set to provide an update on its zotatifin clinical development program in estrogen receptor-positive metastatic breast cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium. They also anticipate topline results from the Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) in Q1 2024. Additionally, a collaboration with Northwestern University for an investigator-initiated Phase 1 dose escalation trial with tomivosertib in patients with Acute Myeloid Leukemia (AML) has been initiated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
earnings
Rhea-AI Summary
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) will participate in a fireside chat discussion and host 1x1 meetings at the 2023 Stifel Healthcare Conference in New York, NY. The Company's CEO will discuss the clinical development pipeline and corporate strategy on November 15 at 12:40 PM ET. A live webcast of the event will be available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.46%
Tags
conferences
eFFECTOR Therapeutics Inc

Nasdaq:EFTR

EFTR Rankings

EFTR Stock Data

55.35M
2.52M
4.44%
21.62%
3.04%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About EFTR

effector therapeutics is a biotechnology company located in 11180 roselle street, san diego, ca, united states.